Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal-cell carcinoma (mRCC)

被引：0
|
作者：
Elena, V.
Iacovelli, R.
Santoni, M.
Di Lorenzo, G.
Cerbone, L.
Ortega, C.
Masini, C.
Giganti, M. O.
Messina, C.
De Vincenzo, F.
Procopio, G.
机构：
[1] Fdn IRCCS Natl Inst Tumors, Milan, Italy
[2] Univ Roma La Sapienza, Oncol Unit, Rome, Italy
[3] Univ Politecn Marche, AO Osped Riuniti, Ancona, Italy
[4] Univ Naples Federico II, Naples, Italy
[5] San Camillo Forlanini Hosp Rome, Rome, Italy
[6] Ist Ric & Cura Canc, Candiolo, Italy
[7] Policlin Modena, Div Med Oncol, Azienda Osped Univ, Modena, Italy
[8] Niguarda Ca Grande Hosp, Milan, Italy
[9] Osped Riuniti Bergamo, Bergamo, Italy
[10] Ist Clin Humanitas, Milan, Italy
来源：
BJU INTERNATIONAL | 2012年 / 110卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
11
引用
收藏
页码：5 / 5
页数：1
相关论文
共 50 条
  • [1] PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS RECEIVING 3 TARGETED THERAPIES (TTS) FOR METASTATIC RENAL-CELL CARCINOMA (MRCC)
    Iacovelli, R.
    Santoni, M.
    Di Lorenzo, G.
    Cerbone, L.
    Aglietta, M.
    Masini, C.
    Giganti, M. O.
    Messina, C.
    Sternberg, C. N.
    Procopio, G.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 270 - 271
  • [2] Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC)
    Verzoni, Elena
    Iacovelli, Roberto
    Rizzo, Mimma
    Felici, Alessandra
    Cascinu, Stefano
    Di Lorenzo, Giuseppe
    Cerbone, Linda
    Ortega, Cinzia
    Masini, Cristina
    Giganti, Maria Olga
    Lorusso, Vito
    Messina, Caterina
    Atzori, Francesco
    De Vincenzo, Fabio
    Sacco, Cosimo
    Boccardo, Francesco
    Valduga, Francesco
    Massari, Francesco
    Tassi, Renato
    Procopio, Giuseppe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [3] OVERALL SURVIVAL (OS) IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS' SEQUENTIALLY TREATED WITH TARGETED THERAPIES (TTS)
    Procopio, G.
    Verzoni, E.
    Testa, I.
    de Braud, F.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 24 - 24
  • [4] Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Halabi, S.
    Rini, B. I.
    Stadler, W. M.
    Small, E. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Castro, Daniela
    Tripathi, Nishita
    Sayegh, Nicolas
    Gebrael, Georges
    Li, Xiaochen
    Meza, Luis
    Zengin, Zeynep
    Chehrazi-Raffle, Alex
    Govindarajan, Ameish
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Chawla, Neal
    Mercier, Benjamin
    Hsu, Joann
    Shi, Jessica
    Philip, Errol
    Bergerot, Cristiane
    Barragan-Carrillo, Regina
    Pal, Sumanta
    [J]. ONCOLOGIST, 2023, 28 : S5 - +
  • [6] Progression-free survival (PFS) and overall survival (OS) across ethnicities for patients with metastatic renal cell carcinoma (mRCC) receiving targeted therapies (TT) as first-line (1L) treatment
    Salgia, Nicholas
    Dizman, Nazli
    Bergerot, Paulo Gustavo
    Bergerot, Cristiane Decat
    Hsu, Joann
    Pal, Sumanta K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [7] Progression-free survival (PFS) of first-line VEGF-targeted therapy as a prognostic parameter for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
    Seidel, C.
    Fenner, M.
    Reuter, C. W.
    Ganser, A.
    Gruenwald, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] OVERALL SURVIVAL (OS) IN METASTATIC RENAL CELL CARCINOMA (MRCC) SEQUENTIALLY TREATED WITH DIFFERENT TARGETED THERAPIES (TTS): RESULTS FROM A LARGE COHORT OF PATIENTS
    Procopio, G.
    Verzoni, E.
    Testa, I.
    Iacovelli, R.
    Garanzini, E.
    De Braud, F. G. M.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 272 - 273
  • [9] Overall survival (OS) in metastatic renal cell carcinoma (mRCC) sequentially treated with different targeted therapies (TTs): Results from a large cohort of patients
    Procopio, Giuseppe
    Verzoni, Elena
    Iacovelli, Roberto
    Testa, Isabella
    Salvioni, Roberto
    Nicolai, Nicola
    Porcu, Luca
    De Braud, Filippo G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Use of early tumor shrinkage as a response to VEGF inhibitors as a predictor of progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Gruenwald, Viktor
    Seidel, Christoph
    Fenner, Martin
    Woike, Michael
    Kalanovic, Daniel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345